

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Comparison of in vitro activity (MIC) of seven antibiotics for exclusive use in humans between *Staphylococcus pseudintermedius* and *Staphylococcus aureus***

**This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1839394> since 2022-02-08T15:52:41Z

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

# Comparison of *in vitro* activity (MIC) of seven antibiotics for exclusive use in humans between *Staphylococcus pseudintermedius* and *Staphylococcus aureus*



A. Bellato, P. Robino, M.C. Stella, D. Scalas, L. Scarrone, P. Nebbia

3<sup>rd</sup> INTERNATIONAL CONFERENCE OF THE  
EUROPEAN COLLEGE OF  
VETERINARY MICROBIOLOGY



## Background

*S. pseudintermedius* is a widespread pathogen of companion animals and many strains carry multiple resistances (Lynch and Helbig, 2021)

Its identification and treatment are made hard due to difficulties in recognition from other *Staphylococcus intermedius* group staphylococci (Murugaiyan et al., 2014)

Occasional infection of pet owners by *S. pseudintermedius* has been reported (Somayaji et al., 2016; Lozano et al., 2017)

## Aim of the study

1. Evaluating the MIC of seven A-category antibiotics (AMEG), namely Ceftaroline, Daptomycin, Linezolid, Quinupristin-Dalfopristin, Teicoplanin, Telavancin, Vancomycin, against *S. pseudintermedius*
2. Comparing our results with MIC distributions reported by EUCAST for *S. aureus*

## Materials and methods

### Sampling

40 clinical samples (31 dogs and 5 cats) from Turin University Veterinary Hospital during two years (July 2019 – May 2021)

Reason for admission: 21 orthopedic surgeries (52.5%), 9 dermatitis (22.5%), 5 soft-tissues surgeries (12.5%), 5 urinary disorders (12.5%)

### Species identification and AST

MALDI-TOF identification confirmed by *nuc* gene PCR (Sasaki et al. 2010)

MIC measured by E-Tests (Liofilchem)

### Statistical analysis

Visual evaluation of MIC and  $\log_2(\text{MIC})$  distributions

Comparison of MIC weighted mean between *S. pseudintermedius* (our sample) and *S. aureus* (EUCAST) by non-parametric tests (Wilcoxon rank-sum)

Adjustment for multiple comparisons (Storey, 2010)

# Results 1/2




Figure 1. Distributions of  $\log_2(\text{MIC})$  for *S. aureus* (EUCAST,  $n = 40609 \pm 32124.69$ ) and *S. pseudintermedius* (our sample,  $n = 40$ ). Data are presented as percentages

## Results 2/2

Only one population of *S. pseudintermedius* identified, thus it was not possible to differentiate between wild-type and resistant strains

The  $\log_2$ (MIC) values of Daptomycin, Linezolid, Quinu-Dalfopristin, and Telavancin were higher for *S. aureus* than *S. pseudintermedius* ( $p < 0.001$ )

The  $\log_2$ (MIC) of Teicoplanin was higher for *S. pseudintermedius* than *S. aureus* ( $p = 0.003$ )

No difference was observed in the  $\log_2$ (MIC) of Ceftaroline and Vancomycin.

## Discussion and conclusion

Referring to *S. aureus* ECOFFs, isolated *S. pseudintermedius* likely belong to wild type for all antibiotics but Ceftaroline

Nonetheless, about Teicoplanin, Vancomycin, Quinu-Dalfopristin and Linezolid some concerns are advisable since strains are susceptible to the upper-limit concentration

# Bibliography

- Lynch, S.A., and Helbig, K.J. (2021). The Complex Diseases of *Staphylococcus pseudintermedius* in Canines: Where to Next? *Veterinary Sciences* 8, 11.
- Murugaiyan, J., Walther, B., Stamm, I., Abou-Elnaga, Y., Brueggemann-Schwarz, S., Vincze, S., Wieler, L.H., Lübke-Becker, A., Semmler, T., Roesler, U. (2014). Species differentiation within the *Staphylococcus intermedius* group using a refined MALDI-TOF MS database. *Clinical Microbiology and Infection*, 20, 1007-1014.
- Decristophoris, P., Fasola, A., Benaglia, C., Tonolla, M., Petrini, O. (2011). Identification of *Staphylococcus intermedius* Group by MALDI-TOF MS. *Systematic and Applied Microbiology*, 34, 45–51.
- Somayaji, R., Priyantha, M.A.R., Rubin, J.E., Church, D. (2016). Human infections due to *Staphylococcus pseudintermedius*, an emerging zoonosis of canine origin: report of 24 cases. *Diagnostic Microbiology and Infectious Disease*, 85, 471-476.
- Lozano, C., Rezusta, A., Ferrer, I., Pérez-Laguna, V., Zarazaga, M., Ruiz-Lipa, L., Revillo, M.J., Torres, C. (2017). *Staphylococcus pseudintermedius* Human Infection Cases in Spain: Dog-to-Human Transmission. *Vector borne and zoonotic diseases*, 17, 260-270.
- Sasaki, T., Tsubakishita, S., Tanaka, Y., Sakusabe, A., Ohtsuka, M., Hirotaki, S., Kawakami, T., Fukata, T., Hiramatsu, K. (2010). Multiplex-PCR Method for Species Identification of Coagulase-Positive Staphylococci. *Journal of Clinical Microbiology*, 48, 765-769.
- Storey, J.D. (2003). The positive false discovery rate: a Bayesian interpretation and the q-value. *The annals of statistics*, 31, 2013-2035.
- <https://mic.eucast.org/> last access 21/07/2021.